drugset / Trial / NCT00094367
A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)
RandomizedParallel-groupOpen-labelTreatment
Summary
This study was designed to evaluate if subjects who took 600 mg of abacavir and 300 mg of lamivudine once-daily as a single tablet were just as likely to have adverse events compared to subjects who took 300 mg of abacavir and 150 mg of lamivudine administered as separate tablets twice-daily.
Timeline
- Start
- 2004-07
- Primary completion
- 2005-10
- Completion
- 2005-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abacavir | Other / unclassified | 300 mg | — |
| Subject | Abacavir | Other / unclassified | 600 mg | — |
| Subject | Lamivudine | Other / unclassified | 150 mg | — |
| Subject | Lamivudine | Other / unclassified | 300 mg | — |